Meeting
2018 ASCO Annual Meeting
Distinct impacts of KRAS, NRAS and BRAF mutations on survival of patients with metastatic colorectal cancer.
Authors
Yucai Wang
Mayo Clinic, Rochester, MN
Yucai Wang , Jonathan M. Loree , Cecilia Yu , Marcella Tschautscher , Andrew M. Briggler , Michael J. Overman , Russell Broaddus , Funda Meric-Bernstam , Jeremy Clifton Jones , Jessica Balcom , Benjamin Kipp , Scott Kopetz , Axel Grothey
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 36, 2018 (suppl; abstr 3513)
DOI
10.1200/JCO.2018.36.15_suppl.3513
Abstract #
3513
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Comprehensive landscape of BRAF variant classes, clonalities, and comutations in metastatic colorectal cancer using ctDNA profiling.
First Author: Benny Johnson
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Prognostic effect of RAS/BRAF mutations in patients (pts) with metastatic colorectal cancer (mCRC).
First Author: Haisam Abid
Poster
2017 Gastrointestinal Cancers Symposium
A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.
First Author: Amanda Rose Townsend
Poster
2015 Gastrointestinal Cancers Symposium
Exploratory RAS analysis of the phase Ib/II 20060447 trial of rilotumumab (R) or ganitumab (G) plus panitumumab (pmab) versus pmab alone in patients (pts) with previously treated metastatic colorectal cancer (mCRC).
First Author: Cathy Eng